石药集团(01093.HK)3款产品於中国全国药品集中采购招标中拟中选
石药集团(01093.HK)公布,公司三款产品於中国全国药品集中采购招标中拟中选,有关药物分别为阿莫西林胶囊,拟中选价格2.16元人民币(下同),供应省份为内蒙古、浙江、四川、西藏及陕西。阿奇霉素片拟中选价格4.98元,供应省份为北京、天津、浙江、湖南、广东、贵州、陕西、青海及新疆(含兵团)。注射用紫杉醇(白蛋白结合型)拟中选价格747元,供应省份为河北、山西、辽宁、吉林、黑龙江、江苏、湖南、广东、贵州、陕西及青海。
公司表示,有关产品於招标中的拟中选价格均低於其各自於市场的现行售价,惟有关产品於招标中成功中选将有助提高该等产品的销量。公司另外两款产品盐酸克林霉素胶囊及头孢氨苄胶囊则未有於招标中成功中选。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.